Supreme Court Favors Medtronic, Licensees In Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
The court found that a patent holder must prove infringement, even when a company licensing a patent is the one filing the lawsuit. The decision favors Medtronic over Boston Scientific in this dispute over cardiac resynchronization therapy patents, and, more broadly, gives more leverage to licensees in patent disputes.
You may also be interested in...
Fed Circuit: Inventor’s Family Should Pick Up Medtronic Lawyer Fees
The decision is a coda to a 2014 Federal Circuit verdict that an implantable cardioverter defibrillator patent held by Mirowski Family Ventures was invalid. About $6m in attorney’s fees were at stake.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?